Table 1.

Characteristics of the participants at baseline and follow-up

No.	Sex	Clinical characteristics				At baseline				12 wk after treatment
		Age (yr)	BW (kg)	Diagnosis	Genetic diagnosis	24-h proteinuria (g/m2)	Plasma albumin (g/l)	eGFR (ml/minper 1.73 m2)	BMI (kg/m2)	24-h proteinuria (g/m2)	Plasma albumin (g/l)	eGFR (ml/minper 1.73 m2)	BMI (kg/m2)
1	F	11.2	47.5	Proteinuria	PAX2	2.35	38.7	72.8	25.1	1.45	43.0	73.2	24.8
2	F	13.8	43.7	Proteinuria	NUP160	2.63	33.4	126.2	16.6	2.29	34.8	110.9	16.4
3	M	9.8	33.6	Dent disease	CLCN5	1.64	47.5	102.7	18.4	1.26	51.6	97.6	18.1
4a	M	11.9	42.2	Alport syndrome	COL4A5	6.21	24.9	60.8	17.2	-	-	-	-
5	M	8.1	24	Alport syndrome	COL4A5	2.42	34.2	113.1	15.6	1.75	35.3	112.5	15.3
6	F	14.2	43.4	Alport syndrome	COL4A3	1.84	31.5	128.9	18.8	1.56	31.7	123.9	20.3
7	M	6.4	24.2	Alport syndrome	COL4A5	1.23	38.0	103.1	15.7	1.22	37.0	100.7	15.5
8	M	8.4	28.2	Alport syndrome	COL4A5	6.18	24.1	163.6	19.3	4.28	25.3	150.6	18.9
9b	F	9.4	27	FSGS	Negative	1.28	34.9	63.3	13.4	0.55	41.1	60.8	14.2

BMI, body mass index; BW, body weight; eGFR, estimated glomerular filtration rate; F, female; FSGS, focal segmental glomerular sclerosis; M, male.

^aPatient 4 was loss to follow-up at the first 4 wk.

^bPatient 9 was with familial FSGS.